Aspira Women's Health Inc. focuses on women's health diagnostics, particularly in the area of ovarian cancer detection through its proprietary tests. The company operates primarily in the United States, leveraging its unique biomarker technology to differentiate itself in a competitive market.
Business Overview
Aspira generates revenue primarily through its diagnostic tests, which are priced based on the complexity and value of the insights they provide. The company benefits from a unique competitive advantage through its proprietary biomarker technology, which enhances the accuracy of ovarian cancer detection, thus allowing for premium pricing.
Regulatory approvals for new tests and technologies
Partnerships with healthcare providers and insurance companies
Market adoption rates of diagnostic tests
Changes in reimbursement policies for diagnostic services
Risk Factors
Regulatory changes affecting diagnostic testing approvals
Technological disruption from emerging diagnostic methods
Increased competition from established diagnostics companies
Potential entry of new players with innovative technologies
Negative operating cash flow impacting liquidity
High reliance on external funding for R&D and operations
Macro Sensitivity
moderate - The demand for diagnostic services can be influenced by overall healthcare spending, which is tied to GDP growth.
Low - As a healthcare company, Aspira's operations are not significantly impacted by interest rates, although higher rates could affect overall healthcare spending.
minimal - The company has a negative debt/equity ratio, indicating limited reliance on debt financing.
Profile
growth - Investors looking for companies with innovative technologies and high growth potential in the healthcare sector.
high - The stock has experienced significant price fluctuations, indicative of its high beta.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
